{
  "relevance_rule": {
    "rule_text": "All abstracts that have client provided keywords",
    "approach": "keywords",
    "key_concepts": {
      "keywords": [
        "Hyperphosphatemia",
        "Parathyroid hormone",
        "Calcitriol",
        "Chronic kidney disease",
        "ESRD",
        "Phosphate binder",
        "Sevelamer",
        "sucroferric oxyhydroxide",
        "lanthanum carbonate",
        "Ferric citrate",
        "Calcium acetate",
        "Constipation",
        "Tenapanor",
        "Claudins",
        "FGF receptor",
        "Albuminuria",
        "nicotinamide",
        "vitamin D",
        "SGLT2 inhibitors",
        "canagliflozin",
        "Dapagliflozin",
        "Empagliflozin",
        "Ozempic",
        "Calcium carbonate",
        "Serum phosphate",
        "Phosphate",
        "Fibroblast growth factor 23",
        "Hemodialysis",
        "Dialysis",
        "Dialysis Outcomes and Practice Patterns Study",
        "Sodium hydrogen transport exchanger 3",
        "sodium-dependent phosphate cotransporter 2b",
        "KDIGO",
        "KDOQI",
        "Sodium",
        "Phosphorus",
        "Klotho",
        "Tight junctions",
        "Occludins",
        "Vascular calcification",
        "Bristol Stool Form Scale",
        "Interdialytic weight gain",
        "peritoneal dialysis",
        "NTX1942",
        "SLC34A2",
        "Glomerular",
        "CKD-MBD",
        "Smooth muscle calcification",
        "Oxylanthanum carbonate"
      ],
      "categories": [],
      "contextual_concepts": []
    },
    "reasoning": "This rule explicitly states that relevance is determined by the presence of client provided keywords."
  },
  "priority_rules": [
    {
      "priority": "High",
      "rule_text": "Phase 2 data, Phase 3 data (including meta-analyses), real-world data (including PROs and registry data), Phosphate binders/phosphate lowering treatment; EXCLUDE Ardelyx sponsored abstracts",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 2",
          "Phase II",
          "Phase 3",
          "Phase III",
          "meta-analysis",
          "real-world data",
          "PROs",
          "patient reported outcomes",
          "registry data",
          "Phosphate binder",
          "phosphate lowering treatment"
        ],
        "categories": [
          "Clinical trial phase",
          "Real-world evidence",
          "Treatment type"
        ],
        "contextual_concepts": [
          "Meta-analyses",
          "Registry data",
          "Patient reported outcomes"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored"
      ],
      "reasoning": "This rule requires both keyword and contextual understanding (e.g., real-world data, PROs, registry data) and must exclude Ardelyx sponsored abstracts to be mutually exclusive with the Internal priority."
    },
    {
      "priority": "Internal",
      "rule_text": "Ardelyx sponsored abstracts",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Ardelyx sponsored",
          "Ardelyx"
        ],
        "categories": [
          "Sponsorship"
        ],
        "contextual_concepts": []
      },
      "exclusions": [],
      "reasoning": "This rule is based on sponsorship and can be identified by keywords."
    },
    {
      "priority": "Medium",
      "rule_text": "Phase 1 data, retrospective analyses, prognostic studies, trial designs, preclinical studies; studies with trial outcomes and endpoints; other general studies; EXCLUDE Phase 2/3, real-world data, phosphate binder/lowering treatment, Ardelyx sponsored abstracts",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 1",
          "Phase I",
          "retrospective analysis",
          "prognostic study",
          "trial design",
          "preclinical study",
          "trial outcomes",
          "endpoints",
          "general study"
        ],
        "categories": [
          "Clinical trial phase",
          "Study type"
        ],
        "contextual_concepts": [
          "Trial outcomes",
          "Endpoints",
          "General studies"
        ]
      },
      "exclusions": [
        "Phase 2",
        "Phase II",
        "Phase 3",
        "Phase III",
        "meta-analysis",
        "real-world data",
        "PROs",
        "patient reported outcomes",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment",
        "Ardelyx sponsored"
      ],
      "reasoning": "This rule covers a broad set of study types and outcomes, requiring both keyword and contextual analysis, and must exclude higher priority categories and Ardelyx sponsored abstracts."
    },
    {
      "priority": "Low",
      "rule_text": "All abstracts that only have mention of an indication and does not include any other data; EXCLUDE all abstracts with any data (Phase 1/2/3, real-world, preclinical, outcomes, endpoints, Ardelyx sponsored, phosphate binder/lowering treatment)",
      "approach": "context",
      "key_concepts": {
        "keywords": [],
        "categories": [
          "Indication only"
        ],
        "contextual_concepts": [
          "No data presented",
          "Indication mention without results or study details"
        ]
      },
      "exclusions": [
        "Phase 1",
        "Phase I",
        "Phase 2",
        "Phase II",
        "Phase 3",
        "Phase III",
        "meta-analysis",
        "real-world data",
        "PROs",
        "patient reported outcomes",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment",
        "preclinical study",
        "trial outcomes",
        "endpoints",
        "Ardelyx sponsored"
      ],
      "reasoning": "This rule requires semantic/contextual understanding to identify abstracts that only mention an indication and do not present any data, and must exclude all abstracts with any data or sponsorship."
    }
  ]
}